1 of 3
“The Global Parkinson's Disease Therapeutics Market to Grow USD 7,522.33 Million by 2025, at a CAGR of 7.09%”
FEATURED COMPANIES
- Abbvie, Inc.
- Apotex, Inc.
- Cipla, Inc.
- Daiichi Sankyo Company
- H. Lundbeck A/S
- Mylan N.V.
- MORE
The Global Parkinson's Disease Therapeutics Market is expected to grow from USD 4,985.67 Million in 2019 to USD 7,522.33 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.09%.
Market Segmentation & Coverage:
This research report categorizes the Parkinson's Disease Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
The Intestinal Infusion is projected to witness the highest growth during the forecast period
Based on Type, the Parkinson's Disease Therapeutics Market studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal. The Oral commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Intestinal Infusion is expected to grow at the fastest CAGR during the forecast period.
The Anticholinergic is projected to witness the highest growth during the forecast period
Based on Drug Class, the Parkinson's Disease Therapeutics Market studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor. The Carbidopa/Levodopa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Anticholinergic is expected to grow at the fastest CAGR during the forecast period.
The Online Pharmacy is projected to witness the highest growth during the forecast period
Based on Distribution Channel, the Parkinson's Disease Therapeutics Market studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy. The Hospital Pharmacy commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Online Pharmacy is expected to grow at the fastest CAGR during the forecast period.
The Clinic is projected to witness the highest growth during the forecast period
Based on End Use, the Parkinson's Disease Therapeutics Market studied across Clinic and Hospital. The Hospital commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Clinic is expected to grow at the fastest CAGR during the forecast period.
The Asia-Pacific is projected to witness the highest growth during the forecast period
Based on Geography, the Parkinson's Disease Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Parkinson's Disease Therapeutics Market including Abbvie, Inc., ACADIA Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies, Inc., Boehringer Ingelheim International GmbH, Cipla, Inc., Daiichi Sankyo Company, H. Lundbeck A/S, Mylan N.V., Novartis AG, Orion Corporation, Par Pharmaceutical by Endo International PLC, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and WOCKHARDT.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Parkinson's Disease Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Parkinson's Disease Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Parkinson's Disease Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Parkinson's Disease Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Parkinson's Disease Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Parkinson's Disease Therapeutics Market?
6. What are the modes and strategic moves considered suitable for entering the Global Parkinson's Disease Therapeutics Market?
Market Segmentation & Coverage:
This research report categorizes the Parkinson's Disease Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
The Intestinal Infusion is projected to witness the highest growth during the forecast period
Based on Type, the Parkinson's Disease Therapeutics Market studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal. The Oral commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Intestinal Infusion is expected to grow at the fastest CAGR during the forecast period.
The Anticholinergic is projected to witness the highest growth during the forecast period
Based on Drug Class, the Parkinson's Disease Therapeutics Market studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor. The Carbidopa/Levodopa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Anticholinergic is expected to grow at the fastest CAGR during the forecast period.
The Online Pharmacy is projected to witness the highest growth during the forecast period
Based on Distribution Channel, the Parkinson's Disease Therapeutics Market studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy. The Hospital Pharmacy commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Online Pharmacy is expected to grow at the fastest CAGR during the forecast period.
The Clinic is projected to witness the highest growth during the forecast period
Based on End Use, the Parkinson's Disease Therapeutics Market studied across Clinic and Hospital. The Hospital commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Clinic is expected to grow at the fastest CAGR during the forecast period.
The Asia-Pacific is projected to witness the highest growth during the forecast period
Based on Geography, the Parkinson's Disease Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Parkinson's Disease Therapeutics Market including Abbvie, Inc., ACADIA Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies, Inc., Boehringer Ingelheim International GmbH, Cipla, Inc., Daiichi Sankyo Company, H. Lundbeck A/S, Mylan N.V., Novartis AG, Orion Corporation, Par Pharmaceutical by Endo International PLC, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and WOCKHARDT.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Parkinson's Disease Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Parkinson's Disease Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Parkinson's Disease Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Parkinson's Disease Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Parkinson's Disease Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Parkinson's Disease Therapeutics Market?
6. What are the modes and strategic moves considered suitable for entering the Global Parkinson's Disease Therapeutics Market?
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Abbvie, Inc.
- Apotex, Inc.
- Cipla, Inc.
- Daiichi Sankyo Company
- H. Lundbeck A/S
- Mylan N.V.
- MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. Executive Summary
3.1. Market Outlook
3.2. Type Outlook
3.3. Drug Class Outlook
3.4. Distribution Channel Outlook
3.5. End Use Outlook
3.6. Geography Outlook
3.7. Competitor Outlook
4. Market Overview
4.1. Introduction
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Growing aging population and the associated Increase in the prevalence of Parkinson’s disease
5.2.2. Development of new therapies and minimally invasive new devices
5.3. Restraints
5.3.1. Availability of alternative treatments
5.4. Opportunities
5.4.1. Increasing pace of R&D by the government in the U.S., the UK, and other countries for Parkinson's disease management
5.4.2. Strong drug pipeline under clinical research
5.4.3. Potential for pharmaceutical companies due to patent expiry
5.5. Challenges
5.5.1. Sales erosion due to expiry of patents
6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations
7. Global Parkinson's Disease Therapeutics Market, By Type
7.1. Introduction
7.2. Intestinal Infusion
7.3. Oral
7.4. Subcutaneous
7.5. Transdermal
8. Global Parkinson's Disease Therapeutics Market, By Drug Class
8.1. Introduction
8.2. Anticholinergic
8.3. Carbidopa/Levodopa
8.4. COMT Inhibitor
8.5. Dopamine Receptor Agonist
8.6. MAO Inhibitor
9. Global Parkinson's Disease Therapeutics Market, By Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retailer Pharmacy
10. Global Parkinson's Disease Therapeutics Market, By End Use
10.1. Introduction
10.2. Clinic
10.3. Hospital
11. Global Parkinson's Disease Therapeutics Market, By Geography
11.1. Introduction
11.2. Americas
11.2.1. Argentina
11.2.2. Brazil
11.2.3. Canada
11.2.4. Mexico
11.2.5. United States
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Indonesia
11.3.5. Japan
11.3.6. Malaysia
11.3.7. Philippines
11.3.8. South Korea
11.3.9. Thailand
11.4. Europe, Middle East & Africa
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Netherlands
11.4.5. Qatar
11.4.6. Russia
11.4.7. Saudi Arabia
11.4.8. South Africa
11.4.9. Spain
11.4.10. United Arab Emirates
11.4.11. United Kingdom
12. Competitive Strategic Window
12.1. Introduction
12.2. Competitive Strategic Window, by Type
12.3. Competitive Strategic Window, by Drug Class
12.4. Competitive Strategic Window, by Distribution Channel
12.5. Competitive Strategic Window, by End Use
12.6. Competitive Strategic Window, by Geography
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbvie, Inc.
14.2. ACADIA Pharmaceuticals, Inc.
14.3. Amneal Pharmaceuticals, Inc.
14.4. Apotex, Inc.
14.5. Bausch Health Companies, Inc.
14.6. Boehringer Ingelheim International GmbH
14.7. Cipla, Inc.
14.8. Daiichi Sankyo Company
14.9. H. Lundbeck A/S
14.10. Mylan N.V.
14.11. Novartis AG
14.12. Orion Corporation
14.13. Par Pharmaceutical by Endo International PLC
14.14. Sun Pharmaceutical Industries Limited
14.15. Teva Pharmaceutical Industries Ltd.
14.16. UCB S.A.
14.17. WOCKHARDT
15. Appendix
15.1. Discussion Guide
15.2. Edition Details
15.3. License Details
15.4. Pricing Details
LIST OF FIGURES
FIGURE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2019 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019 VS 2025 (USD MILLION)
FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2019 VS 2025 (USD MILLION)
FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 9. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, BY TYPE
FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2025 (USD MILLION)
FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE GROWTH , 2017-2025 (USD MILLION)
FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: MARKET DYNAMICS
FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
FIGURE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
FIGURE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2019 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 19. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 20. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2025
FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2025
FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
LIST OF TABLES
TABLE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2025 (USD MILLION)
TABLE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 21. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 22. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 23. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 24. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 25. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 26. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 27. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 28. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 29. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 30. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 31. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 32. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 33. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 34. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 35. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 36. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 37. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 38. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 39. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 40. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 41. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 42. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 43. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 44. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 45. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 46. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 47. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 48. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 49. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 50. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 51. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 52. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 53. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 54. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 55. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 56. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 57. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 58. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 59. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 60. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 61. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 62. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 63. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 64. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 65. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 66. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 67. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 68. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 69. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 70. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 71. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 72. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 73. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 74. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 75. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 76. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 77. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 78. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 79. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 80. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 81. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 82. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 83. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 84. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 85. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 86. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 92. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 93. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 94. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 95. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 96. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 97. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 98. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 99. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 100. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 101. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 102. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 103. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 104. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 105. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 106. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 107. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 108. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 109. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 110. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 111. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 112. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 113. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 114. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 115. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 116. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 117. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 118. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 119. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 120. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 121. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 122. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 123. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 124. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 125. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 126. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 127. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 132. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 133. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 134. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 135. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 136. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: SCORES
TABLE 137. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 138. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 139. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RANKING
TABLE 140. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 141. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 142. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 143. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 144. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 145. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: EDITION DETAILS
TABLE 146. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: LICENSE DETAILS
TABLE 147. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PRICING DETAILS
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. Executive Summary
3.1. Market Outlook
3.2. Type Outlook
3.3. Drug Class Outlook
3.4. Distribution Channel Outlook
3.5. End Use Outlook
3.6. Geography Outlook
3.7. Competitor Outlook
4. Market Overview
4.1. Introduction
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Growing aging population and the associated Increase in the prevalence of Parkinson’s disease
5.2.2. Development of new therapies and minimally invasive new devices
5.3. Restraints
5.3.1. Availability of alternative treatments
5.4. Opportunities
5.4.1. Increasing pace of R&D by the government in the U.S., the UK, and other countries for Parkinson's disease management
5.4.2. Strong drug pipeline under clinical research
5.4.3. Potential for pharmaceutical companies due to patent expiry
5.5. Challenges
5.5.1. Sales erosion due to expiry of patents
6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations
7. Global Parkinson's Disease Therapeutics Market, By Type
7.1. Introduction
7.2. Intestinal Infusion
7.3. Oral
7.4. Subcutaneous
7.5. Transdermal
8. Global Parkinson's Disease Therapeutics Market, By Drug Class
8.1. Introduction
8.2. Anticholinergic
8.3. Carbidopa/Levodopa
8.4. COMT Inhibitor
8.5. Dopamine Receptor Agonist
8.6. MAO Inhibitor
9. Global Parkinson's Disease Therapeutics Market, By Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retailer Pharmacy
10. Global Parkinson's Disease Therapeutics Market, By End Use
10.1. Introduction
10.2. Clinic
10.3. Hospital
11. Global Parkinson's Disease Therapeutics Market, By Geography
11.1. Introduction
11.2. Americas
11.2.1. Argentina
11.2.2. Brazil
11.2.3. Canada
11.2.4. Mexico
11.2.5. United States
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Indonesia
11.3.5. Japan
11.3.6. Malaysia
11.3.7. Philippines
11.3.8. South Korea
11.3.9. Thailand
11.4. Europe, Middle East & Africa
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Netherlands
11.4.5. Qatar
11.4.6. Russia
11.4.7. Saudi Arabia
11.4.8. South Africa
11.4.9. Spain
11.4.10. United Arab Emirates
11.4.11. United Kingdom
12. Competitive Strategic Window
12.1. Introduction
12.2. Competitive Strategic Window, by Type
12.3. Competitive Strategic Window, by Drug Class
12.4. Competitive Strategic Window, by Distribution Channel
12.5. Competitive Strategic Window, by End Use
12.6. Competitive Strategic Window, by Geography
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbvie, Inc.
14.2. ACADIA Pharmaceuticals, Inc.
14.3. Amneal Pharmaceuticals, Inc.
14.4. Apotex, Inc.
14.5. Bausch Health Companies, Inc.
14.6. Boehringer Ingelheim International GmbH
14.7. Cipla, Inc.
14.8. Daiichi Sankyo Company
14.9. H. Lundbeck A/S
14.10. Mylan N.V.
14.11. Novartis AG
14.12. Orion Corporation
14.13. Par Pharmaceutical by Endo International PLC
14.14. Sun Pharmaceutical Industries Limited
14.15. Teva Pharmaceutical Industries Ltd.
14.16. UCB S.A.
14.17. WOCKHARDT
15. Appendix
15.1. Discussion Guide
15.2. Edition Details
15.3. License Details
15.4. Pricing Details
LIST OF FIGURES
FIGURE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2019 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019 VS 2025 (USD MILLION)
FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2019 VS 2025 (USD MILLION)
FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 9. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, BY TYPE
FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2025 (USD MILLION)
FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE GROWTH , 2017-2025 (USD MILLION)
FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: MARKET DYNAMICS
FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
FIGURE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
FIGURE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2019 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 19. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 20. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2025
FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2025
FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
LIST OF TABLES
TABLE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2025 (USD MILLION)
TABLE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 21. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 22. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 23. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 24. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 25. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 26. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 27. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 28. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 29. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 30. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 31. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 32. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 33. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 34. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 35. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 36. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 37. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 38. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 39. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 40. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 41. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 42. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 43. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 44. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 45. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 46. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 47. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 48. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 49. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 50. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 51. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 52. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 53. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 54. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 55. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 56. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 57. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 58. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 59. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 60. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 61. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 62. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 63. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 64. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 65. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 66. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 67. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 68. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 69. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 70. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 71. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 72. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 73. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 74. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 75. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 76. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 77. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 78. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 79. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 80. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 81. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 82. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 83. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 84. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 85. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 86. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 92. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 93. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 94. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 95. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 96. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 97. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 98. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 99. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 100. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 101. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 102. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 103. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 104. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 105. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 106. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 107. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 108. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 109. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 110. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 111. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 112. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 113. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 114. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 115. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 116. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 117. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 118. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 119. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 120. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 121. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 122. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 123. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 124. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 125. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 126. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 127. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 132. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
TABLE 133. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 134. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
TABLE 135. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
TABLE 136. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: SCORES
TABLE 137. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 138. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 139. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RANKING
TABLE 140. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 141. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 142. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 143. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 144. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 145. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: EDITION DETAILS
TABLE 146. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: LICENSE DETAILS
TABLE 147. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PRICING DETAILS
Note: Product cover images may vary from those shown
3 of 3
- Abbvie, Inc.
- ACADIA Pharmaceuticals, Inc.
- Amneal Pharmaceuticals, Inc.
- Apotex, Inc.
- Bausch Health Companies, Inc.
- Boehringer Ingelheim International GmbH
- Cipla, Inc.
- Daiichi Sankyo Company
- H. Lundbeck A/S
- Mylan N.V.
- Novartis AG
- Orion Corporation
- Par Pharmaceutical by Endo International PLC
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
- WOCKHARDT
Note: Product cover images may vary from those shown
